<DOC>
	<DOCNO>NCT01163929</DOCNO>
	<brief_summary>The primary objective study ass whether combination chemotherapy , Trastuzumab RAD001 result evidence microscopic disease time surgery 50 % enrolled patient .</brief_summary>
	<brief_title>A Study Look Combination Chemotherapy , Trastuzumab RAD001 HER2 Positive Breast Cancer</brief_title>
	<detailed_description>This open-label Phase 2 neoadjuvant study patient histologically confirm , HER-2 positive operable breast cancer . All patient receive 18 week neoadjuvant treatment . The trial initial 2 week `` biomarker lead '' phase . During two week phase patient either receive Trastuzumab alone Trastuzumab + Everolimus . This two week lead phase randomize open label . The rest 16 week neoadjuvant trial treatment non randomize open label . For first two week neoadjuvant treatment eligible subject randomly assign either receive receive Everolimus . This assignment accomplish previously prepared schedule ( maintain investigational pharmacy ) , investigator unaware assignment subject enrol study receive assignment Everolimus .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female ≥ 18 65 year age Histologically proven stage I , II III adenocarcinoma breast Candidate adjuvant chemotherapy Trastuzumab ( Tumor size &gt; 1 cm , T2 , T3 , T4 and/or clinical N1 N2 ) HER2 positive breast cancer ( IHC 3+ FISH ratio &gt; 2.0 ) ECOG Performance status 02 No prior chemotherapy HER2 target therapy breast cancer Not pregnant breast feeding adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . Hormonal contraceptives acceptable sole method contraception . Women childbearing potential must negative urine serum pregnancy test within 7 day administration RAD001 Adequate bone marrow function : ANC &gt; 1500/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 11 g/dL Adequate kidney function : serum creatinine &lt; 1.5mg/dl and/or creatinine clearance &gt; 60 mL/min Adequate hepatic function : transaminase &lt; 2 x upper limit normal total bilirubin &lt; 1.5 mg/dL . INR ≤2.0 PTT 1.5 X upper limit institution normal range . Oral anticoagulant , eg , warfarin CYP2C9 substrates , interaction RAD001 expect . Anticoagulation Coumadin allow target INR ≤2.0 stable &gt; 2 week . Anticoagulation LMWH allow . Must sign inform consent Pretreatment lab value CBC CMP perform within 14 day registration baseline study within 30 day . Will baseline mammogram , bone scan , CT chest abdomen within 60 day registration . Adequate cardiac function ( Cardiac ejection fraction ≥ 50 % measure echocardiogram MUGA scan ) . Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Prior HER2 target therapy breast cancer Metastatic disease Uncontrolled intercurrent illness include limited , ongoing active infection require parenteral antibiotic psychiatric illness/social situation would limit compliance study requirement . GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease eg , Crohn 's , ulcerative colitis ) . Current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone ) Renal function measure creatinine clearance &lt; 30ml/min ( ratio norm &lt; 0.1 ) Pregnant Inflammatory breast cancer Active cardiac disease , define : History uncontrolled symptomatic angina History arrhythmia require medication , clinically significant , exception asymptomatic atrial fibrillation require anticoagulation Myocardial infarction &lt; 6 month study entry Uncontrolled symptomatic congestive heart failure Any cardiac condition , opinion treat physician , would make protocol unreasonably hazardous patient History another primary cancer , exception : curatively resect nonmelanomatous skin cancer curatively treat cervical carcinoma insitu primary solid tumor curatively resect , treat know active disease present treatment administer last 3 year . Life expectancy &lt; 2 month Receiving chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Should receive immunization attenuate live vaccine within 1 week study entry study period Severely impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN Active ( acute chronic ) uncontrolled severe infection Known history HIV seropositivity Active , bleed diathesis Patients receive prior treatment mTOR inhibitor ( Sirolimus , Temsirolimus , Everolimus ) . Known hypersensitivity RAD001 ( Everolimus ) rapamycins ( Sirolimus , Temsirolimus ) excipients Active Hepatitis B C infection &gt; 65 year age</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Phase II</keyword>
	<keyword>RAD001</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>everolimus</keyword>
</DOC>